Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2010
08/26/2010US20100216826 Polymorphisms in Voltage-Gated Sodium Channel Alpha 1-Subunit as Markers for Therapy Selection
08/26/2010US20100216824 Anti-cancer cyclopenta [G]quinazonline compounds
08/26/2010US20100216823 Spirocyclic Derivatives
08/26/2010US20100216822 Nucleotide Analogue Prodrug and the Preparation Thereof
08/26/2010US20100216821 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists
08/26/2010US20100216820 Thienopyrimidiones for treatment of inflammatory disorders and cancers
08/26/2010US20100216819 Thiazolopyrimidines for Use in Therapy
08/26/2010US20100216818 Inhibitors of Post-Amadori Advanced Glycation End Products
08/26/2010US20100216817 Antitumoral Tetrahydro-Pyrimidines
08/26/2010US20100216816 Pyrazinyl amide-t type calcium channel antagonists
08/26/2010US20100216815 N-substituted oxindoline derivatives as calcium channel blockers
08/26/2010US20100216814 Pyrido[4,3-b]indoles containing rigid moieties
08/26/2010US20100216813 Pyrrolidineanilines
08/26/2010US20100216812 Cyclopropyl Amide Derivatives
08/26/2010US20100216811 Furo[3. 2-b] pyrrol derivatives
08/26/2010US20100216810 Heterocyclic compound and use thereof
08/26/2010US20100216809 Piperidine/piperazine derivatives
08/26/2010US20100216808 Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
08/26/2010US20100216807 Heterocyclic compounds as serotonergic and / or dopaminergic agents and uses thereof
08/26/2010US20100216806 Ortho aminoamides for the treatment of cancer
08/26/2010US20100216805 Modulation of neurogenesis using d-cycloserine combinations
08/26/2010US20100216804 Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
08/26/2010US20100216803 Ornithine derivative
08/26/2010US20100216802 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
08/26/2010US20100216801 Thiazolones for use as pi3 kinase inhibitors
08/26/2010US20100216800 Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione
08/26/2010US20100216799 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
08/26/2010US20100216798 Fused heterocycles as lck inhibitors
08/26/2010US20100216797 Preparation of thioarabinofuranosyl compounds and use thereof
08/26/2010US20100216796 N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
08/26/2010US20100216795 Tnik inhibitor and the use
08/26/2010US20100216794 Pyridine derivatives useful as glucokinase activators
08/26/2010US20100216793 Heteroaryl substituted pyridazinone derivatives
08/26/2010US20100216791 Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
08/26/2010US20100216790 Imidazopyridine-derivatives as inducible no-synthase inhibitors
08/26/2010US20100216789 Rho-kinase inhibitors
08/26/2010US20100216788 Fused heterocyclic compound
08/26/2010US20100216787 Thiazole derivative
08/26/2010US20100216786 New compounds
08/26/2010US20100216785 Pharmaceutical compositions
08/26/2010US20100216784 Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds
08/26/2010US20100216783 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
08/26/2010US20100216782 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
08/26/2010US20100216781 mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
08/26/2010US20100216780 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
08/26/2010US20100216779 Imidazopyridine Kinase Inhibitors
08/26/2010US20100216778 Pain remedy containing rock inhibitor
08/26/2010US20100216777 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
08/26/2010US20100216776 Assays for S100 inhibitors
08/26/2010US20100216775 Adamantanamines and Neramexane Salts of Thiomolybdic and Thiotungstic Acids
08/26/2010US20100216774 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
08/26/2010US20100216773 Phenanthroindolizidine analogues
08/26/2010US20100216772 Novel Phenantridine Analogues and Uses Thereof
08/26/2010US20100216771 Method oftreating demyelination diseases
08/26/2010US20100216770 Inhibitors of the Interaction Between MDM2 and P53
08/26/2010US20100216769 Substituted glycinamides, process for their manufacture and use thereof as medicaments
08/26/2010US20100216768 N-substituted azaindoles and methods of use
08/26/2010US20100216767 Quinazolines for pdk1 inhibition
08/26/2010US20100216766 Inhibitors of VEGF Receptor and HGF Receptor Signalling
08/26/2010US20100216765 Kinase inhibitors
08/26/2010US20100216764 Soluble Guanylate Cyclase Activators
08/26/2010US20100216763 Heteroaryl Amide Derivatives
08/26/2010US20100216762 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof
08/26/2010US20100216761 Novel azetidinones useful as inhibitors of elastase
08/26/2010US20100216760 Novel compounds as cannabinoid receptor ligands
08/26/2010US20100216759 Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia
08/26/2010US20100216758 Pyridone Compounds
08/26/2010US20100216757 Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase
08/26/2010US20100216756 Compositions and methods for suppressing endometrial proliferation
08/26/2010US20100216755 Anti-tumor agent
08/26/2010US20100216754 Compositions for the treatment of inflammation of the gastrointestinal tract
08/26/2010US20100216753 Controlled release of drugs into/through the skin
08/26/2010US20100216752 Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process
08/26/2010US20100216751 Liquid Bevirimat Dosage Forms for Oral Administration
08/26/2010US20100216750 Tricyclic inhibitors of fatty acid amide hydrolase
08/26/2010US20100216749 Combination Therapy for Neuroprotection
08/26/2010US20100216748 Pyrrole Derivatives and Their Methods of Use
08/26/2010US20100216747 Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism
08/26/2010US20100216746 Chemical compounds
08/26/2010US20100216745 Novel cephem compounds useful for the treatment of bacterial infections
08/26/2010US20100216743 Therapy-enhancing glucan
08/26/2010US20100216742 Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
08/26/2010US20100216741 Ophthalmic composition
08/26/2010US20100216740 Cereal-based Infant Nutrition with Fibre
08/26/2010US20100216739 Method of promoting muscle tissue repair
08/26/2010US20100216737 Inactivation of miR-34a by abberant CpG methylation in cancer
08/26/2010US20100216736 2'-cyanopyrimidine nucleoside compound
08/26/2010US20100216735 Gpcr enhanced neuroprotection to treat brain injury
08/26/2010US20100216734 Modulation of neurogenesis by nootropic agents
08/26/2010US20100216733 Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis
08/26/2010US20100216732 Azithromycin for the treatment of nodular acne
08/26/2010US20100216731 Process for the preparation of macrolide antibacterial agents
08/26/2010US20100216729 Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts
08/26/2010US20100216728 New use of specific cyklolignans
08/26/2010US20100216727 Carbohydrate-metallocene-antimalarial conjugates
08/26/2010US20100216726 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
08/26/2010US20100216719 Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
08/26/2010US20100216716 Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway
08/26/2010US20100216710 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
08/26/2010US20100216709 Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy
1 ... 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 ... 7860